DDH Chat
Gastroparesis Advocate Shares the Importance of Finding Your Community IFFGD talks to gastroparesis advocate and IFFGD Patient Advisory Committee member, Stephanie Torres, about her journey and the importance of finding your voice and your community. For many, the journey from symptom onset to long-term symptom management is a long and winding one, taking twists and […]
Testimony
On September 12, 2017, Ceciel Rooker presented the following research information to the US Food and Drug Administration (FDA) concerning the burdens and needs of gastroparesis patients: On behalf of the International Foundation for Functional Gastrointestinal Disorders (IFFGD), we appreciate the opportunity provided by the FDA to hear the patient perspective at the Patient-Focused Drug […]
Testimony
The following written comments were submitted to the Office of Disability Policy of the Social Security Administration (SSA) by IFFGD President, Ceciel T. Rooker, in response to Docket No. SSA-2017-0042 on September 23, 2019. Thank you for your leadership at the Office of Disability Policy. The International Foundation for Gastrointestinal Disorders (IFFGD) is grateful for the […]
Testimony
IFFGD Vice-President, William Norton, submitted the following written public testimony to the FDA in connection with an October 16, 2012 meeting of the Gastrointestinal Drugs Advisory Committee to consider the new drug application (NDA) 203441 by NPS Pharmaceuticals for the drug with the proposed trade name GATTEX® (teduglutide) for the treatment of adult patients with […]
Testimony
On December 2, 2010, Dane Christiansen provided the following testimony on behalf of IFFGD members to the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee regarding the consideration of the Ocean Theapeutics’ product Solesta for the treatment of incontinence: Good afternoon. My name is Dane Christiansen and I am here today representing […]
Testimony
IFFGD President and Co-Founder, Nancy J. Norton submitted the following written statement on October 25, 2012 to the Food and Drug Administration Division of Dockets Management in response to docket number: FDA-2012-N-0967, the Prescription Drug User Fee Act Patient-Focused Drug Development Meeting: Thank you for the opportunity to present the views of the International Foundation […]
The application window is now closed The International Foundation for Gastrointestinal Disorders (IFFGD) is now accepting applications for the IFFGD 2026 Preceptorship Award. At IFFGD, our mission is deeply patient-centered — we are committed to improving the lives of those affected by gastrointestinal (GI) disorders. This award supports that mission by investing in the next […]
The application window is now closed The International Foundation for Gastrointestinal Disorders (IFFGD) is now accepting applications and nominations for the IFFGD 2026 Travel Awards. These awards recognize and support early-career clinicians and researchers dedicated to advancing understanding and treatment of functional gastrointestinal (GI) and motility disorders. Learn more about the IFFGD Nancy and Bill […]
The application window is now closed The International Foundation for Gastrointestinal Disorders (IFFGD) is pleased to announce that we are seeking applications for our 2026 research grant. The mission of IFFGD is patient oriented. Our goal is to fund high-quality research. Learn more about the IFFGD Nancy and Bill Norton Research Program About the 2026 […]
✨ Part One | Complementary and Integrative Health Tools for GI Patients Living with a gastrointestinal (GI) disorder can be challenging — but complementary and integrative health tools may help improve symptoms, reduce stress, and support overall well-being. In this first episode of our two-part series, Dr. Elyse Thakur, Director of Clinical Psychology at Atrium […]
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and […]